Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Epizyme, Inc.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
The German biotech had already hinted at possibly expanding through M&A, and Constellation was viewed as an attractive acquisition target.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.